Carbenicillin plus cefamandole in the treatment of infections in patients with cancer.
The combination of carbenicillin plus cefamandole was administered to 88 patients with cancer during 116 evaluable episodes of fever. The overall response rate to carbenicillin plus cefamandole for the 116 episodes was 57%. There were 60 documented infections, of which 60% responded to this combination of antibiotics. The response rate was only 43% in patients with pneumonia. The etiologic agent was identified during 38 infections, of which 74% responded to carbenicillin plus cefamandole. Responses occurred less frequently in patients with neutropenia than in those without neutropenia and less frequently in patients whose infection was caused by organisms resistant to both antibiotics than in those with infection caused by organisms sensitive to one or both of the drugs. No side effects could be attributed to the antibiotic regimen.
D000293:Adolescent; D000333:Aeromonas; D000368:Aged; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy*; D002228:Carbenicillin / Q000627:therapeutic use*; D002435:Cefamandole / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D003354:Corynebacterium Infections / Q000188:drug therapy; D004359:Drug Therapy, Combination; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D005260:Female; D005417:Flavobacterium; D006801:Humans; D008088:Listeriosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D012141:Respiratory Tract Infections / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy; D014031:Tobramycin / Q000627:therapeutic use
D002511:Cephalosporins; D002435:Cefamandole; D002228:Carbenicillin; D014031:Tobramycin